Pieter A van Doorn

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi request reprint Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS)
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Presse Med 42:e193-201. 2013
  2. pmc Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
    Deniz Güngör
    Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Dr, Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Orphanet J Rare Dis 6:34. 2011
  3. pmc Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome
    Elham Barkhordari
    Department of Gastroenterology and Hepatology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
    J Clin Immunol 30:74-9. 2010
  4. doi request reprint Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
    Pieter A van Doorn
    Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
    Lancet Neurol 7:939-50. 2008
  5. doi request reprint How to assess new drugs for neuropathies: advances in trial design and methodology
    Pieter A van Doorn
    Department of Neurology, Erasmus MC Rotterdam, The Netherlands
    Curr Opin Neurol 21:519-26. 2008
  6. doi request reprint What's new in Guillain-Barré syndrome in 2007-2008?
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    J Peripher Nerv Syst 14:72-4. 2009
  7. ncbi request reprint IVIG treatment and prognosis in Guillain-Barré syndrome
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Room BA 450, s Gravendijkwal 230, Rotterdam, The Netherlands
    J Clin Immunol 30:S74-8. 2010
  8. ncbi request reprint Treatment of Guillain-Barré syndrome and CIDP
    Pieter A van Doorn
    Department of Neurology, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Peripher Nerv Syst 10:113-27. 2005
  9. ncbi request reprint Treatment of chronic inflammatory demyelinating polyneuropathy
    Pieter A van Doorn
    Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Curr Opin Neurol 17:607-13. 2004
  10. doi request reprint Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Peripher Nerv Syst 16:38-40. 2011

Detail Information

Publications86

  1. doi request reprint Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS)
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Presse Med 42:e193-201. 2013
    ..Hopefully these and other studies will further help to improve the understanding and especially the outcome in patients with GBS...
  2. pmc Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
    Deniz Güngör
    Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Dr, Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Orphanet J Rare Dis 6:34. 2011
    ..Our objective was to determine the survival of adults with Pompe disease not receiving ERT and to identify prognostic factors associated with survival...
  3. pmc Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome
    Elham Barkhordari
    Department of Gastroenterology and Hepatology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
    J Clin Immunol 30:74-9. 2010
    ..Proinflammatory cytokines can play an important role in intestinal inflammation, while their production is under genetic control...
  4. doi request reprint Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
    Pieter A van Doorn
    Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
    Lancet Neurol 7:939-50. 2008
    ..Advances in prognostic modelling have resulted in the development of a new and simple prognostic outcome scale that might also help to guide new treatment options, particularly in patients with GBS who have a poor prognosis...
  5. doi request reprint How to assess new drugs for neuropathies: advances in trial design and methodology
    Pieter A van Doorn
    Department of Neurology, Erasmus MC Rotterdam, The Netherlands
    Curr Opin Neurol 21:519-26. 2008
    ....
  6. doi request reprint What's new in Guillain-Barré syndrome in 2007-2008?
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    J Peripher Nerv Syst 14:72-4. 2009
    ..This suggests trials of Eculizumab in GBS should be considered. Unfortunately, there are no new randomized controlled trials in GBS to report although the unmet need is great...
  7. ncbi request reprint IVIG treatment and prognosis in Guillain-Barré syndrome
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Room BA 450, s Gravendijkwal 230, Rotterdam, The Netherlands
    J Clin Immunol 30:S74-8. 2010
    ..These clinical factors were combined in a clinical prognostic scoring scale, the Erasmus GBS Outcome Scale (EGOS)...
  8. ncbi request reprint Treatment of Guillain-Barré syndrome and CIDP
    Pieter A van Doorn
    Department of Neurology, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Peripher Nerv Syst 10:113-27. 2005
    ..Therefore, new treatment trials are highly indicated. This review focuses on the current and possible new treatment options that could be guided by recent results from laboratory experiments...
  9. ncbi request reprint Treatment of chronic inflammatory demyelinating polyneuropathy
    Pieter A van Doorn
    Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Curr Opin Neurol 17:607-13. 2004
    ..The most up-to-date treatment options are discussed. Attention is also paid to the use of appropriate assessment scales and treatment of residual findings...
  10. doi request reprint Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP
    Pieter A van Doorn
    Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Peripher Nerv Syst 16:38-40. 2011
    ....
  11. doi request reprint Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome
    Bart C Jacobs
    Department of Neurology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    J Neuroimmunol 194:181-90. 2008
    ..These findings support a model in which C. jejuni and H. influenzae infections induce two distinct patterns of cross-reactive antibodies with different clinical outcome...
  12. ncbi request reprint Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome
    Karin Geleijns
    Department of Neurology, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
    J Neuroimmunol 190:127-30. 2007
    ..The MMP9 C(-1562)T and TNFA C(-863)A SNP were associated with severe weakness and poor outcome, indicating that these SNP may be one of the factors predisposing to a severe form of GBS...
  13. ncbi request reprint Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome
    Karin Geleijns
    Department of Neurology, Erasmus MC, Dr Molewaterplein 50, Rotterdam, 3015 GE, The Netherlands
    J Neuroimmunol 161:183-9. 2005
    ....
  14. doi request reprint Limb motor nerve dysfunction in Miller Fisher syndrome
    Judith Drenthen
    Department of Clinical Neurophysiology, Erasmus MC, University Medical Center, 3000 CA Rotterdam, The Netherlands
    J Peripher Nerv Syst 18:25-9. 2013
    ..CMAP scanning is a sensitive technique for early detection of subclinical motor nerve dysfunction and for monitoring disease activity in immune-mediated neuropathies...
  15. pmc Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study
    Nadine A M E van der Beek
    Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Orphanet J Rare Dis 7:88. 2012
    ..Furthermore, we defined the natural disease course and identified prognostic factors for disease progression...
  16. doi request reprint Guillain-Barré syndrome subtypes related to Campylobacter infection
    Judith Drenthen
    Department of Clinical Neurophysiology, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 82:300-5. 2011
    ..In The Netherlands C jejuni is the predominant type of preceding infection yet AMAN is rare. This may indicate that not all Dutch GBS patients with C jejuni infections have AMAN...
  17. ncbi request reprint Prediction of respiratory insufficiency in Guillain-Barré syndrome
    Christa Walgaard
    Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Ann Neurol 67:781-7. 2010
    ..We aimed to develop a simple but accurate model to predict the chance of respiratory insufficiency in the acute stage of the disease based on clinical characteristics available at hospital admission...
  18. ncbi request reprint Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients
    Karin Geleijns
    Department of Immunology, Erasmus Medical Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Neuroimmunol 150:132-8. 2004
    ..Comparison of the genotypes of 242 GBS patients and 210 healthy subjects showed that polymorphisms in CD14 and TLR4 did not confer disease susceptibility and were not associated with C. jejuni infection...
  19. ncbi request reprint Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome
    Karin Geleijns
    Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Immunol 177:4211-7. 2006
    ..These results support the hypothesis that complement activation mediated by MBL contributes to the extent of nerve damage in GBS, which is codetermined by the MBL2 haplotype...
  20. doi request reprint Residual fatigue in Guillain-Barre syndrome is related to axonal loss
    Judith Drenthen
    From the Departments of Clinical Neurophysiology J D, E M M, G H V, J H B, Neurology J D, B C J, P A v D, and Immunology B C J, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Neurology 81:1827-31. 2013
    ..To determine the occurrence of residual loss of peripheral nerve axons by motor unit number estimation (MUNE) and conventional nerve conduction studies (NCS) in patients with and without severe fatigue...
  21. ncbi request reprint Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk
    Johanna M P Van den Hout
    Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC Sophia, Rotterdam, Rotterdam, The Netherlands
    Pediatrics 113:e448-57. 2004
    ..Loss of muscle strength prevents infants from achieving developmental milestones such as sitting, standing, and walking. Milder forms of the disease are associated with less severe mutations and partial deficiency of alpha-glucosidase...
  22. doi request reprint Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease
    Stephan C A Wens
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Mol Genet Metab 107:485-9. 2012
    ..We investigated the genotype-phenotype correlation in three such adult patients and measured the GAA activity as well as the glycogen content in muscle and fibroblasts in order to better understand the clinical course...
  23. doi request reprint Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome
    Marieke J H J Dekker
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Peripher Nerv Syst 14:75-83. 2009
    ..In conclusion, GR haplotypes are not a susceptibility factor for GBS. However, haplotypes carrying the minor allele of the BclI polymorphism were related to the phenotype and outcome of GBS...
  24. ncbi request reprint TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation
    Mark L Kuijf
    Department of Neurology, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
    J Immunol 185:748-55. 2010
    ..jejuni LOS enhances human DC activation and subsequent B cell proliferation, which may contribute to the development of cross-reactive anti-ganglioside Abs found in GBS patients following C. jejuni infection...
  25. doi request reprint Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms
    Mark L Kuijf
    Department of Neurology, Erasmus MC, s Gravendijkwal 230, 3015CE, Rotterdam, The Netherlands
    J Neuroimmunol 205:110-2. 2008
    ..Based on this study, CD1 polymorphisms are not a susceptibility or disease modifying factor in GBS...
  26. doi request reprint Enzyme replacement therapy and fatigue in adults with Pompe disease
    Deniz Güngör
    Center for Lysosomal and Metabolic Diseases, Department of Pediatrics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Mol Genet Metab 109:174-8. 2013
    ..Pompe disease is a hereditary metabolic myopathy, for which enzyme replacement therapy (ERT) has been available since 2006. We investigated whether ERT reduces fatigue in adult patients with Pompe disease...
  27. doi request reprint Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy
    Krista Kuitwaard
    Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Room Ee 2230, PO Box 2040, Rotterdam 3000 CA, The Netherlands
    J Neurol Neurosurg Psychiatry 84:859-61. 2013
    ..To determine the variability of serum IgG in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)...
  28. pmc Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study
    Juna M de Vries
    Department of Neurology and Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Orphanet J Rare Dis 7:73. 2012
    ..We investigated whether it alters the course of disease, and also identified potential prognostic factors...
  29. ncbi request reprint Multiplet discharges after electrical stimulation: new evidence for distal excitability changes in motor neuron disease
    Ellen M Maathuis
    Department of Clinical Neurophysiology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Amyotroph Lateral Scler 13:514-20. 2012
    ..Analysis of MD characteristics provides further indications for pathophysiological excitability changes in the most distal part of the motor neuron. MDs are associated with clinical deterioration...
  30. ncbi request reprint Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA
    Mark L Kuijf
    Department of Neurology, Erasmus Medical Center, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    J Neurol Sci 239:37-44. 2005
    ..High IgM titers were associated with GBS and multifocal motor neuropathy. Low IgM titers had no additional diagnostic value. The INCAT-ELISA is a reliable test with additional diagnostic value in specific clinical situations...
  31. pmc AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands
    Catharina G Faber
    Department of Neurology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, The Netherlands
    J Neurol 256:1719-23. 2009
    ....
  32. doi request reprint Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome
    Krista Kuitwaard
    Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Ann Neurol 66:597-603. 2009
    ..IVIg clearance may depend on disease severity and vary between individuals, implying that this dose is suboptimal for some patients. In this study, we determined whether the pharmacokinetics of IVIg is related to outcome in GBS...
  33. ncbi request reprint Origin of ganglioside complex antibodies in Guillain-Barré syndrome
    Mark L Kuijf
    Department of Neurology, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
    J Neuroimmunol 188:69-73. 2007
    ..jejuni strain. Previous mass spectrometry studies on these LOS showed the presence of oligosaccharides with a similar structure, further supporting the hypothesis that in these patients LOS induced the ganglioside complex antibodies...
  34. doi request reprint Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes
    Frans Brugman
    Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
    Arch Neurol 66:509-14. 2009
    ..Differentiation between these diseases is important for genetic counseling and prognostication...
  35. ncbi request reprint A clinical prognostic scoring system for Guillain-Barré syndrome
    Rinske van Koningsveld
    Department of Neurology, Erasmus MC, Rotterdam, Netherlands
    Lancet Neurol 6:589-94. 2007
    ..We aimed to develop and validate a scoring system based on clinical characteristics in the acute phase of GBS to predict outcome at 6 months...
  36. pmc Determination of pain and response to methylprednisolone in Guillain-Barré syndrome
    Liselotte Ruts
    Dept of Neurology, Erasmus MC, Room number Ee 2230, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    J Neurol 254:1318-22. 2007
    ..Pain can be a serious problem in patients with Guillain-Barré syndrome (GBS). Different pain symptoms and the effect of methylprednisolone on pain are evaluated...
  37. pmc Phenotypical variation within 22 families with Pompe disease
    Stephan C A Wens
    Department of Neurology, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Orphanet J Rare Dis 8:182. 2013
    ..We hypothesized that siblings and families with the same genotype share more similar phenotypes than the total population of non-classic Pompe patients, and that this might reveal genotype-phenotype correlations...
  38. doi request reprint The CMAP scan as a tool to monitor disease progression in ALS and PMA
    Ellen M Maathuis
    Department of Clinical Neurophysiology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Amyotroph Lateral Scler Frontotemporal Degener 14:217-23. 2013
    ..01). In conclusion, the CMAP scan can be used to visualize and quantify disease progression in a muscle affected by MND. The CSPS is a measure of MU loss that is quick and easy to obtain and that, in contrast to MUNE, has no sample bias...
  39. pmc The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients
    Carine I van Capelle
    Department of Pediatrics, Division of Metabolic Diseases and Genetics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Postbus 2060, 3000 CB, Rotterdam, The Netherlands
    J Inherit Metab Dis 35:317-23. 2012
    ..In conclusion, the Quick Motor Function Test can reliably rate clinical severity and motor function in children and adults with Pompe disease...
  40. doi request reprint Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale
    Sonja I van Nes
    Department of Neurology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
    J Peripher Nerv Syst 14:268-78. 2009
    ..In conclusion, a 7-item linearly weighted Rasch-built modified FSS is presented for more proper assessment of fatigue in future studies in patients with immune-mediated neuropathies...
  41. doi request reprint Revised normative values for grip strength with the Jamar dynamometer
    Martine J H Peters
    Department of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands
    J Peripher Nerv Syst 16:47-50. 2011
    ..Hand dominance had no influence. Other personal factors only minimally influenced final values. This study provides revised normative GS values for the Jamar dynamometer...
  42. ncbi request reprint Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations
    Liselotte Ruts
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Neurology 65:138-40. 2005
    ..Maintenance treatment should then be considered...
  43. ncbi request reprint Contribution of central and peripheral factors to residual fatigue in Guillain-Barré syndrome
    Marcel P J Garssen
    Department of Neurology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Muscle Nerve 36:93-9. 2007
    ..This study thus provides further insight into the factors contributing to residual fatigue in GBS patients...
  44. ncbi request reprint Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up
    Leon P F Winkel
    Department of Pediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC Sophia, Rotterdam, The Netherlands
    Ann Neurol 55:495-502. 2004
    ..There is good reason to continue the development of enzyme replacement therapy for Pompe's disease and to explore further the production of human therapeutic proteins in the milk of mammals...
  45. doi request reprint Mortality in Guillain-Barre syndrome
    Bianca van den Berg
    Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Neurology 80:1650-4. 2013
    ..To determine the frequency, timing, causes, and risk factors of death in Guillain-Barré syndrome (GBS)...
  46. doi request reprint First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease
    Juna M de Vries
    Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Mol Genet Metab 104:552-5. 2011
    ..In this case report, the continuation of treatment with alglucosidase alfa during pregnancy and lactation has been safe for the mother and the child...
  47. doi request reprint Recurrences, vaccinations and long-term symptoms in GBS and CIDP
    Krista Kuitwaard
    Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Peripher Nerv Syst 14:310-5. 2009
    ..Flu vaccinations seem relatively safe. GBS and CIDP patients often experience pain, fatigue and a reduced quality of life for many years after the diagnosis...
  48. doi request reprint Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study
    Ingemar S J Merkies
    Department of Neurology, Spaarne Hospital, Hoofddorp, The Netherlands
    J Peripher Nerv Syst 15:208-15. 2010
    ..24) was explained by impairment and activity and participation measures. Future studies are required to elucidate the impact of CIDP on disability and QoL changes, because the obtained correlations provide only partial explanation...
  49. doi request reprint ANO5 mutations in the Dutch limb girdle muscular dystrophy population
    Anneke J van der Kooi
    Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Neuromuscul Disord 23:456-60. 2013
    ..Muscle biopsy showed predominantly dystrophic changes. One patient had hypertrophic cardiomyopathy, two others had intraventricular septum thickening...
  50. ncbi request reprint Comparison between impairment and disability scales in immune-mediated polyneuropathies
    Ingemar S J Merkies
    Department of Neurology, University Hospital Rotterdam Erasmus University, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Muscle Nerve 28:93-100. 2003
    ..Hence, the primary use of these measures is suggested in studies of immune-mediated polyneuropathies...
  51. ncbi request reprint Immunotherapy for Guillain-Barré syndrome
    Pieter A van Doorn
    Erasmus Medical Center, Department of Neurology, Dr Molewaterplein 40, 3015 Rotterdam, The Netherlands
    Lancet Neurol 3:84. 2004
  52. pmc Hearing in adults with Pompe disease
    Nadine A M E van der Beek
    Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    J Inherit Metab Dis 35:335-41. 2012
    ..Therefore, we conclude that hearing loss is not a specific feature of Pompe disease in adults...
  53. ncbi request reprint Conduction velocity distribution in neurologically well-recovered but fatigued Guillain-Barré syndrome patients
    Marcel P J Garssen
    Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Muscle Nerve 33:177-82. 2006
    ..These changes were most pronounced in the subgroup of patients with the lowest fatigue scores. We therefore conclude that the observed CVD changes in patients are not likely to contribute to persisting complaints of fatigue after GBS...
  54. doi request reprint Emerging drugs for Guillain-Barré syndrome
    Christa Walgaard
    University Medical Centre, Department of Neurology, Erasmus MC, Room Ee 2230, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Expert Opin Emerg Drugs 16:105-20. 2011
    ..However, this treatment is insufficient for many patients as 1 - 5% die, 25% need artificial respiration, 20% are still unable to walk unaided after 6 months and 85% have residual symptoms, such as fatigue and pain...
  55. ncbi request reprint Treatment of immune neuropathies
    Pieter A van Doorn
    Department of Neurology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Curr Opin Neurol 15:623-31. 2002
    ..Recent therapeutic trials and the question of whether patients with mild disease or other variants of these disorders need to be treated are discussed...
  56. doi request reprint A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers
    Linda E M van den Berg
    Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Neuromuscul Disord 21:232-4. 2011
    ..The cause and clinical effects of fiber type specific involvement are currently unknown, but the phenomenon might contribute to the clinical heterogeneity in Pompe disease and the variable response to enzyme replacement therapy...
  57. doi request reprint Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy
    Krista Kuitwaard
    Department of Neurology, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
    Drugs 69:987-1001. 2009
    ..An overview of these newer treatments, their mode of action, adverse effects and potential place in the spectrum of treatments for CIDP based on previous reports and their level of evidence is given...
  58. ncbi request reprint Increased aortic stiffness and blood pressure in non-classic Pompe disease
    Stephan C A Wens
    Department of Neurology, Erasmus University Medical Center, Mailbox 2040, 3000 CA, Rotterdam, The Netherlands
    J Inherit Metab Dis 37:391-7. 2014
    ..Whether this is due to glycogen accumulation requires further investigation. To reduce the potential risk of cardiovascular diseases, we recommend that blood pressure and other common cardiovascular risk factors are monitored regularly...
  59. doi request reprint IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins
    Willem Jan R Fokkink
    Department of Immunology, Department of Neurology, and Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 50, 3000 CA Rotterdam, The Netherlands
    J Proteome Res 13:1722-30. 2014
    ..In conclusion, our results suggest that serum IgG Fc glycosylation in GBS is related to disease severity and clinical recovery after IVIg and may help to develop new measures to monitor the efficacy of treatment. ..
  60. doi request reprint Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial
    Ivo N van Schaik
    Department of Neurology, Academic Medical Center, University of Amsterdam, Netherlands
    Lancet Neurol 9:245-53. 2010
    ..The PREDICT study aimed to compare remission rates in patients with CIDP treated with high-dose dexamethasone with rates in patients treated with standard oral prednisolone...
  61. ncbi request reprint Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
    Johannes B J Bussmann
    Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Rehabil Med 39:121-5. 2007
    ....
  62. ncbi request reprint The natural course of non-classic Pompe's disease; a review of 225 published cases
    Leon P F Winkel
    Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC Sophia, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    J Neurol 252:875-84. 2005
    ..Studies of non-classic Pompe's disease should focus on these aspects, before enzyme replacement therapy becomes generally available...
  63. ncbi request reprint Congenital hypomyelinating neuropathy, a long term follow-up study in an affected family
    Liesbeth S Smit
    Department of Pediatric Neurology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, PO Box 2060, 3000 CB Rotterdam, The Netherlands
    Neuromuscul Disord 18:59-62. 2008
    ..Histopathologically there are no or thin myelin sheaths. Mutations have been described in the following genes, MPZ, EGR2, PMP22, and MTMR2. Here we describe a family with a heterozygous mutation in MPZ, confirmed in two generations...
  64. ncbi request reprint Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy
    Sebastiaan Overeem
    Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Neurosci Lett 341:13-6. 2003
    ..However, as an autoimmune attack may be selective and/or transient, future studies are needed to ultimately refute or confirm the autoimmune hypothesis...
  65. doi request reprint High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa
    Juna M de Vries
    Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, Rotterdam, The Netherlands
    Mol Genet Metab 101:338-45. 2010
    ..This case demonstrates that also patients with an appreciable amount of properly folded and catalytically active endogenous acid α-glucosidase can develop antibodies against alglucosidase alfa that affect the response to ERT...
  66. doi request reprint Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recovery
    Liselotte Ruts
    Department of Neurology, Erasmus MC, University of Rotterdam, s Gravendijkwal 230, 3015CE Rotterdam, The Netherlands
    Pain 153:399-409. 2012
    ..IENFD declines early, remains low over time, correlates with pain severity in the acute phase, and may predict long-term disability...
  67. ncbi request reprint Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress
    A Cecile J W Janssens
    Erasmus MC, Department of Neurology, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Epidemiol 57:180-6. 2004
    ..The aim of the study was to investigate the impact of perception of prognostic risk on anxiety, depression, and disease-related distress in patients with multiple sclerosis (MS)...
  68. ncbi request reprint TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations
    Harro Seelaar
    Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Brain 130:1375-85. 2007
    ..NII are also found in some cases of familial FTD + MND without Progranulin mutations. The observation of glial TDP-43 positive inclusions in one brain is very interesting, although their pathophysiological significance is yet unknown...
  69. doi request reprint Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndrome
    Martine E Bos Eyssen
    Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Neurocrit Care 15:128-33. 2011
    ..We investigated the impact of selective decontamination of the digestive tract (SDD), an intervention that reduces hospital acquired infections in ICU patients, on duration of MV in GBS and neurological outcome at 6 months...
  70. ncbi request reprint Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies
    Ingemar S J Merkies
    Department of Neurology, Daniel den Hoed Cancer Center, University Hospital Rotterdam Erasmus University, Rotterdam, The Netherlands
    Muscle Nerve 25:370-7. 2002
    ..These results illustrate the clinical usefulness of the Rotterdam nine-item handicap scale under these conditions...
  71. ncbi request reprint Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients
    Dragan Buljevac
    Department of Neurology, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Ann Neurol 54:828-31. 2003
    ..CP polymerase chain reaction was positive in most of the CP seropositive patients. No correlation was found between the anti-CP antibody increase and titers of control antibodies...
  72. pmc Does a carpal tunnel syndrome predict an underlying disease?
    Maarten C de Rijk
    Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 78:635-7. 2007
    ..In general, systematic screening for incident diabetes mellitus, hypothyroidism and CTD through additional blood tests seems to be of little additional value in otherwise typical cases of CTS...
  73. ncbi request reprint Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo
    Umesh A Badrising
    Department of Neurology, Leiden University Medical Center, The Netherlands
    Ann Neurol 51:369-72. 2002
    ..Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity...
  74. ncbi request reprint Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy
    Leon P F Winkel
    Department of Pediatrics, Erasmus MC Sophia, Rotterdam, The Netherlands
    Muscle Nerve 27:743-51. 2003
    ..We conclude that intravenous administration of recombinant human alpha-glucosidase from rabbit milk can improve muscle morphology in classic infantile Pompe's disease when treatment is started before irreversible damage has occurred...
  75. pmc Fatigue: an important feature of late-onset Pompe disease
    Marloes L C Hagemans
    Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC Sophia, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    J Neurol 254:941-5. 2007
    ..To investigate the prevalence and severity of fatigue in adult patients with Pompe disease...
  76. doi request reprint Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
    Lancet Neurol 7:136-44. 2008
    ..We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP...
  77. ncbi request reprint Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors
    Nina M van Sorge
    Department of Neurology and Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Ann Neurol 53:570-9. 2003
    ..These data document the capacity of anti-GM1 IgG antibodies to activate leukocyte inflammatory functions, and suggest an important role for anti-ganglioside IgG antibodies in the pathogenesis of GBS...
  78. ncbi request reprint Immunotherapy for Guillain-Barré syndrome: a systematic review
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Campus, London, UK
    Brain 130:2245-57. 2007
    ..Since approximately 20% of patients die or have persistent disability despite immunotherapy, more research is needed to identify better treatment regimens and new therapeutic strategies...
  79. ncbi request reprint Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude
    Ingemar S J Merkies
    Neurology 63:1138; author reply 1138. 2004
  80. ncbi request reprint Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms
    Nina M van Sorge
    Department of Neurology G03 228, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Neuroimmunol 162:157-64. 2005
    ..Results suggest that Fc gammaRIII genotypes may represent mild disease-modifying factors in GBS...
  81. ncbi request reprint Predicting the course of Guillain-Barré syndrome
    Pieter A van Doorn
    Lancet Neurol 5:991-3. 2006
  82. ncbi request reprint Transient hypertrichosis in a patient with Guillain-Barré syndrome
    Liselotte Ruts
    J Peripher Nerv Syst 12:290-2. 2007
  83. ncbi request reprint Presence or absence of cytomegalovirus in cerebrospinal fluid from patients with Guillain-Barré syndrome?
    Mark L Kuijf
    J Infect Dis 193:1471-2; author reply 1472-3. 2006
  84. pmc Multifocal motor neuropathy with abrupt onset and spontaneous recovery
    Carel Bulens
    J Neurol 254:966-7. 2007
  85. ncbi request reprint Increased aortic stiffness in glycogenosis type 2 (Pompe's disease)
    Attila Nemes
    Int J Cardiol 120:138-41. 2007
    ..The current study was designed to assess aortic stiffness index (beta), as a characteristic of aortic elasticity during transthoracic echocardiography in patients with Pompe's disease...